Company Overview - Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [2] - The company is advancing its lead compound, Lucid-MS, which is designed to prevent and reverse myelin degradation, a key factor in multiple sclerosis, and is currently in preclinical development [2] Analyst Coverage - Kingswood Capital Partners has initiated coverage of Quantum BioPharma with a BUY rating and a price target of US$45, contingent on successful Phase 2 and 3 trials of Lucid-MS between 2026 and 2028, with a commercial launch anticipated in 2029 [1] - The lead analyst for this report is Karen Sterling, PhD, CFA, Senior Equity Analyst at Kingswood Capital Partners [1] Financial Interests - Quantum BioPharma retains a 20.10% ownership stake in Unbuzzd Wellness Inc., which is associated with the unbuzzd™ product, and is entitled to 7% royalty payments on sales until total payments reach $250 million, after which the royalty rate will decrease to 3% indefinitely [2]
Kingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price Target